COMBINATION OF A PDE4 INHIBITOR AND TIOTROPIUM OR DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS AND OTHER INFLAMMATORY DISEASES

Details for Australian Patent Application No. 2002314102 (hide)

Owner BOEHRINGER INGELHEIM PHARMA KG

Inventors WATSON, John, W.; YEADON, Michael; ARMSTRONG, Roisin, A.

Pub. Number AU-A-2002314102

PCT Number PCT/EP02/05643

PCT Pub. Number WO2002/096423

Priority 60/293,555 25.05.01 US; 60/303,845 09.07.01 US

Filing date 23 May 2002

Wipo publication date 9 December 2002

International Classifications

A61K 031/46 - 8-Azabicyclo [3.2.1] octane

A61K 009/72 Medicinal preparations characterised by special physical form - for smoking or inhaling

A61P 011/06 Drugs for disorders of the respiratory system

A61P 011/08 Drugs for disorders of the respiratory system

Event Publications

2 January 2003 Complete Application Filed

  Priority application(s): 60/293,555 25.05.01 US; 60/303,845 09.07.01 US

8 May 2003 Application Open to Public Inspection

  Published as AU-A-2002314102

11 March 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002314103-Use of il-18 inhibitors for treating or preventing cns injuries

2002314101-COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS AND OTHER INFLAMMATORY DISEASES